Peptidhormone LH, FSH, TSH, Prolaktin, β-HCG und PTH bei Patienten mit urogenitalen Tumoren

Dunzendorfer, U; Drahovský, D.; Schmidt‐Gayk, H.

doi:10.1159/000214908

Cited by 4 publications

(5 citation statements)

References 5 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time clinical biochemical research revealed that serum levels of luteinizing hormones (LH), follicle-stimulating hormones (FSH), thyroid-stimulating hormones (TSH), luteotropic hormones (prolactin, PRL), human chorionic gonadotropin (beta-HCG) hormones, and parathyroid hormones (PTH) were significantly modulated in patients with urogenital tumors including RCC. After nephrectomy, PTH was frequently suppressed in these patients (20). Prolactin elevation was found in 45% of ccRCC patients regardless of the stage of the disease.…”

Section: Hormone Signaling Pathways As Treatment Targets In Renal Celmentioning

confidence: 91%

See 1 more Smart Citation

Hormone signaling pathways as treatment targets in renal cell cancer (Review)

Czarnecka

Niedzwiedzka

Porta

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Epidemiological, clinical, biochemical and genetic research has revealed that renal cell cancer (RCC) etiology is hormone-related. It was shown that hormone receptors are abnormally expressed in RCC cells. Abnormal endocrine stimulation also plays a significant role in RCC pathophysiology. Cellular proliferation, migration, angiogenesis, and drug resistance in RCC is modulated by para-and autocrine hormonal stimulation. In particular, RCC overexpression of gonadotropin-releasing hormone and its receptor was reported. On the contrary, corticotropin releasing hormone was reported to inhibit RCC cell proliferation and regulate angiogenesis. Overexpression of luteinizing hormone also promotes RCC tumor angiogenesis. Estrogen receptor α overexpression increases the transcriptional factor activity of hypoxia inducible factor HIF-1α, but estrogen receptor β has a cancer suppressive role. Glucocorticoid receptors and androgen receptor are markers of indolent RCC and assigned tumor suppressive activity. Proopiomelanocortin is upregulated in VHL-mutated renal cell carcinoma via Nur77 transcription factor signaling. In RCC, follicle-stimulating hormone receptor promotes angiogenesis and metastatic formation via VEGF release. Mineralocorticoid receptor overexpression promotes cell survival and increases RCC cell proliferation. Vitamin D receptor expression is downregulated or absent in RCC and differentiate subtypes of renal cell tumors. RAR-β promotes tumorigenesis but retinoic acid receptor γ expression correlates negatively with the TNM stage at diagnosis. Finally, progesterone receptor expression is negatively correlated with the cancer stage. Molecular data analysis revealed the possibility of renal cancer cell proliferation induction via hormone activated pathways. Inhibition of hormonal signaling may thus play a putative role in supportive therapies against this cancer type.

show abstract

Section: Hormone Signaling Pathways As Treatment Targets In Renal Celmentioning

confidence: 91%

“…Even patients without paraneoplastic syndromes experience frequent changes that are directly caused by RCC (20), although only a single case of hyperprolactinemia induced by RCC has thus far been reported (58).…”

Section: Prolactin (Prl)mentioning

confidence: 99%

Hormone signaling pathways as treatment targets in renal cell cancer (Review)

Czarnecka

Niedzwiedzka

Porta

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…For instance, serum androgen level is one of the important indicators in the initial diagnosis of the majority of PrCa ( 30 , 31 ), and clinical endocrine therapy of PrCa is mainly to reduce androgen levels and to inhibit the function of the androgen receptor ( 32 ). Renal cell carcinoma may also be hormone-related cancer, given that clinical studies have found that multiple hormone receptors were highly expressed in RCC tumor tissues ( 33 ) and abnormal hormone levels are of vital importance for RCC development ( 34 , 35 ). In a sense, BRCA, PrCa, and RCC are all hormone-related cancers.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Homocysteine on the Risk of Hormone-Related Cancers: A Mendelian Randomization Study

Yang

Sun

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Background: Aberrant homocysteine level is associated with metabolic disorders and DNA damage, which may be involved in the carcinogenesis of hormone-related cancers, but clinical results of observational studies are controversial. In this study, we investigated the causal relationships between plasma homocysteine and breast cancer (BRCA), prostate cancer (PrCa), and renal cell carcinoma (RCC) using Mendelian randomization (MR) analyses.Design and Methods: To investigate the putative causal associations between homocysteine and the aforementioned three types of cancers, a two-sample MR study was employed for the study. The primary strategy for summary data analyses was the inverse-variance-weighted (IVW) approach. In our study, the single-nucleotide polymorphisms (SNPs) excluded confounding factors through Linkage Disequilibrium (LD). Phenoscanner tests were the instrumental variants (IVs), homocysteine was the exposure, and BRCA, PrCa, and RCC were the outcomes. Single-nucleotide polymorphisms associated with homocysteine were extracted from a large genome-wide association study (GWAS) meta-analysis of European participants (n = 44,147). Summary Statistics of BRCA were obtained from the latest and largest GWAS meta-analysis comprising of 82 studies from Breast Cancer Association Consortium (BCAC) studies, including women of European ancestry (133,384 cases and 113,789 controls); we obtained summary-level data from the GWAS meta-analysis of PrCa comprising 79,148 cases and 61,106 controls of European ancestry, and the dataset of RCC was a sex-specific GWAS meta-analysis comprising of two kidney cancer genome-wide scans for men (3,227 cases and 4,916 controls) and women (1,992 cases and 3,095 controls) of European ancestry. The MR-Egger and weight median analyses were applied for the pleiotropy test.Results: The results showed null associations between plasma homocysteine levels and overall BRCA (effect = 0.97, 95% CI: 0.90–1.06, P = 0.543), overall PrCa (effect = 1.01, 95% CI: 0.93–1.11, P = 0.774), RCC in men (effect = 0.99, 95% CI: 0.73–1.34, P = 0.929), and RCC in women (effect = 0.89, 95% CI: 0.61–1.31, P = 0.563).Conclusions: We found no putative causal associations between homocysteine and risk of BRCA, PrCa, and RCC.

show abstract

“…The authors suggest a possible gonadotropin secretion by the tumor, but there is no definitive diagnosis. We have found three clinical cases of LH secretion, two of them by pancreatic tumors (20,21) and one by an adrenocortical tumor (22), and gonadotropin secretion by urogenital tumors (23). Exceptional cases of ovarian hyperstimulation associated with severe primary hyperthyroidism (24) and with granulosa cell tumors (25) have been described.…”

Section: Case Reportmentioning

confidence: 98%